Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241055 | 1.00 | HPGD (0.53) | HPGDCHRM2CHRM1CHRM3RECQL | |
| SCHEMBL14494 | 1.00 | HPGD (0.53) | HPGDCHRM2CHRM1CHRM3RECQL | |
| SCHEMBL29433963 | 0.98 | HPGD (0.51) | HPGDCHRM2CHRM1CHRM3RECQL | |
| Hydroxyamine SCHEMBL28087664 | 0.96 | HPGD (0.50) | HPGDCHRM2CHRM1CHRM3RECQL | |
| SCHEMBL3530704 | 0.92 | EPHX1 (0.48) | HPGDCHRM2CHRM1CHRM3RECQL | |
| SCHEMBL1068107 | 0.89 | MEN1 (0.56) | HPGDCHRM2CHRM1CHRM3RECQL | |
| SCHEMBL30862413 | 0.89 | MEN1 (0.56) | HPGDCHRM2CHRM1CHRM3RECQL | |
| SCHEMBL190483 | 0.89 | MEN1 (0.56) | HPGDCHRM2CHRM1CHRM3RECQL | |
| SCHEMBL215146 | 0.89 | MEN1 (0.56) | HPGDCHRM2CHRM1CHRM3RECQL | |
| SCHEMBL28126430 | 0.89 | HPGD (0.44) | HPGDCHRM2CHRM1CHRM3RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1993 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110777125-B | Efficient preparation method of heterocyclic drug intermediate | JIANGNAN UNIVERSITY (CN) | 2021-08-31 | — | — | CN | claimed |
| CN-111118559-A | Composition for surface treatment of copper flexible connection | 常州极太汽车配件有限公司 | 2020-05-08 | — | — | CN | claimed |
| CN-110983390-A | Composition for surface treatment of aluminum strip flexible connection | 常州极太汽车配件有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110777125-A | Efficient preparation method of heterocyclic drug intermediate | 江南大学 | 2020-02-11 | — | — | CN | claimed |
| CN-105646321-A | Preparation method of (S)-3-hydroxypyrrolidine hydrochloride | 中国药科大学 | 2016-06-08 | — | — | CN | claimed |
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122080012-A | Thienopyrimidine derivative, preparation method, application and pharmaceutical composition thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122094958-A | PARP1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| CN-122070273-A | Novel process for the preparation of (3R) -fluoropyrrolidine hydrochloride | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122070273-A | Novel process for the preparation of (3R) -fluoropyrrolidine hydrochloride | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-5866577-A | AN ANTICOAGULANT AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-02 | — | — | US | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1997042189-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0394991-B1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5102877-A | Carbapenicillin antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0394991-A1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | HPGD 4284/4885CHRM2 256/4885CHRM1 330/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | HPGD 2931/4885CHRM2 3765/4885CHRM1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.